Revocable Beneficiary

In insurance, a revocable beneficiary is a beneficiary of a life insurance policy or annuity contract whose designation as a beneficiary can be changed by the policy owner or contract holder at any time without the beneficiary's consent. This means that the policy owner has the flexibility to change the beneficiary designation if their circumstances change or if they want to leave the death benefit to someone else.

Here are some key features of a revocable beneficiary:

  • The policy owner has the right to change the beneficiary designation at any time without the consent of the current beneficiary.
  • The revocable beneficiary has no vested interest in the policy or contract and does not have any rights to the benefits until the policy owner dies.
  • If the policy owner does not designate a beneficiary or if the designated beneficiary dies before the policy owner, the death benefit will be paid to the policy owner's estate.
  • A revocable beneficiary designation can be used in both individual and group life insurance policies and annuity contracts.

For example, suppose John has a life insurance policy and names his wife, Jane, as the revocable beneficiary. If John later divorces Jane and marries someone else, he can change the beneficiary designation to his new spouse or to another person without Jane's consent. If John dies while Jane is still the designated beneficiary, she will receive the death benefit. However, if John later changes the beneficiary to his new spouse and dies before changing it back to Jane, the new spouse will receive the death benefit instead.

Next Up

According to Mployer Insights’ 2026 analysis of 76,000+ employer benefit plans, disability insurance remains a major market differentiator, with only 41% of U.S. employers offering short-term disability (STD) and 38% offering long-term disability (LTD). While 60% salary replacement serves as the national standard across both benefit types, standard plan designs disproportionately expose higher earners due to median benefit caps of $1,602/week for STD and $8,273/month for LTD. Furthermore, alignment between STD benefit durations (median 26 weeks) and LTD elimination periods (68% at 90 days) remains a critical area for plan structure optimization.
Welcome to our latest release. We are excited for you to try the new features.
According to Mployer Insights’ 2026 analysis of 50,000+ employer health plans, prescription drugs account for over 25% of total benefit expenses, with Tier 4 specialty drugs driving the majority of high-cost claims. While Tier 4 copays average $123 with coinsurance requirements in 31% of plans, individual oncology therapies like Darzalex Faspro ($170,800/yr) and Keytruda ($158,200/yr) frequently exceed average individual stop-loss deductibles ($141,938). To mitigate exposure, self-funded employers are increasingly turning to independent, transparent PBM models and biosimilar substitution—which yields up to a 73% net cost reduction per patient.